Starting with the ECPKA detection method, we are developing a companion diagnosis (XDX-01) for powering the cancer immunotherapy. KNAX and Xylonix are working together to jointly scale the manufacturing of XDX-01 and conduct broader clinical validation studies.
Collaborating with RIChBiDiT, our pipelines are now expanded to specific cancer and infectious disease diagnostics. In particular, we are striving to develop diagnostic technology that effectively and rapidly detect COVID-19 Pandemics.
